Belimumab added to multi-target therapy in lupus nephritis: a retrospective cohort study of efficacy, divergent temporal response patterns, and safety
Abstract
BackgroundLupus nephritis (LN) is a severe complication of systemic lupus erythematosus. Belimumab, a B-cell-activating factor (BAFF) inhibitor, improves renal outcomes when added to standard therapy, but its efficacy and temporal effects when combined with multi-target therapy regimens containing tacrolimus remain poorly characterized. We compared multi-target therapy plus belimumab with multi-target therapy alone in active LN.MethodsIn this retrospective cohort study, 28 patients with active LN (14 per group) received multi-target therapy (glucocorticoid, mycophenolate mofetil, and tacrolimus, a calcineurin inhibitor) with (case group) or without (control group) belimumab. The patients were assessed at baseline and 3, 6, and 12 months after treatment initiation. Primary endpoints were 24-hour urinary protein (24hUP), estimated glomerular filtration rate (eGFR), and urine protein-to-creatinine ratio (UPCR). C3, C4, anti-dsDNA, SLEDAI-2K, and IgG/IgA/IgM were the secondary endpoints. Comparisons were conducted using Welch’s t or Mann-Whitney U tests (between-group), paired t or Wilcoxon tests (within-group), and Cohen’s d effect sizes.ResultsCompared to baseline, both groups exhibited significant improvement in proteinuria, SLEDAI-2K, anti-dsDNA, and complement. eGFR remained stable, with no significant between-group differences at any timepoint. Temporal patterns diverged: the belimumab group showed earlier reduction in proteinuria (from 3 months) and IgG/IgA/IgM levels, whereas multi-target therapy alone showed earlier recovery of complement levels, with weak C4 recovery after treatment with belimumab. During twelve months of treatment, adverse events were infrequent and comparable between groups (all p = 1.00).ConclusionsBoth regimens substantially improved renal and serological outcomes over 12 months with an acceptable safety profile. Although the addition of belimumab did not significantly outperform multi-target therapy alone, the two regimens exhibited distinct, mechanistically coherent temporal signatures: inhibition of the BAFF pathway versus broad immunosuppression. These findings warrant confirmation in larger prospective studies.
Related
- Cell-type-divergent redox injury in rheumatoid arthritis and systemic lupus erythematosus/lupus nephritis: evidence for ferroptosis-related remodeling and immune amplification
- Divergent interplay between STIM1 and STIM2 sets the efficacy of central synapses
- Prevalence and prognostic significance of extrarenal manifestations in patients with lupus nephritis: A retrospective cohort study
- Divergent Spatial and Temporal Sensitivities of Forest Biomass to Climate Challenge Space-For-Time Assumptions and Models.
- Shared symmetry detection with divergent temporal dynamics in marmosets and humans
BibTeX
@article{da2026belimumab,
title = {{Belimumab added to multi-target therapy in lupus nephritis: a retrospective cohort study of efficacy, divergent temporal response patterns, and safety}},
author = {Gula Da and Youge Su and Yunlong Qu and Xuetong Wang and Xinyue Xiao and Hongbin Li},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1986318},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1986318},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Belimumab added to multi-target therapy in lupus nephritis: a retrospective cohort study of efficacy, divergent temporal response patterns, and safety
AU - Gula Da
AU - Youge Su
AU - Yunlong Qu
AU - Xuetong Wang
AU - Xinyue Xiao
AU - Hongbin Li
PY - 2026
DA - 2026/11/10
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1986318
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1986318
AB - BackgroundLupus nephritis (LN) is a severe complication of systemic lupus erythematosus. Belimumab, a B-cell-activating factor (BAFF) inhibitor, improves renal outcomes when added to standard therapy, but its efficacy and temporal effects when combined with multi-target therapy regimens containing tacrolimus remain poorly characterized. We compared multi-target therapy plus belimumab with multi-target therapy alone in active LN.MethodsIn this retrospective cohort study, 28 patients with active LN (14 per group) received multi-target therapy (glucocorticoid, mycophenolate mofetil, and tacrolimus, a calcineurin inhibitor) with (case group) or without (control group) belimumab. The patients were assessed at baseline and 3, 6, and 12 months after treatment initiation. Primary endpoints were 24-hour urinary protein (24hUP), estimated glomerular filtration rate (eGFR), and urine protein-to-creatinine ratio (UPCR). C3, C4, anti-dsDNA, SLEDAI-2K, and IgG/IgA/IgM were the secondary endpoints. Comparisons were conducted using Welch’s t or Mann-Whitney U tests (between-group), paired t or Wilcoxon tests (within-group), and Cohen’s d effect sizes.ResultsCompared to baseline, both groups exhibited significant improvement in proteinuria, SLEDAI-2K, anti-dsDNA, and complement. eGFR remained stable, with no significant between-group differences at any timepoint. Temporal patterns diverged: the belimumab group showed earlier reduction in proteinuria (from 3 months) and IgG/IgA/IgM levels, whereas multi-target therapy alone showed earlier recovery of complement levels, with weak C4 recovery after treatment with belimumab. During twelve months of treatment, adverse events were infrequent and comparable between groups (all p = 1.00).ConclusionsBoth regimens substantially improved renal and serological outcomes over 12 months with an acceptable safety profile. Although the addition of belimumab did not significantly outperform multi-target therapy alone, the two regimens exhibited distinct, mechanistically coherent temporal signatures: inhibition of the BAFF pathway versus broad immunosuppression. These findings warrant confirmation in larger prospective studies.
SN - 1664-3224
ER -